期刊
ONCOTARGETS AND THERAPY
卷 15, 期 -, 页码 651-657出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S364566
关键词
FGFR fusion; lung adenocarcinoma; anlotinib; ERC1; NGS
资金
- National Natural Science Foundation [82060547]
- Jiangxi Provincial Natural Science Foundation [20212BAB206051]
This case report demonstrates that anlotinib may be an effective treatment option for NSCLC patients with an FGFR2-ERC1 fusion gene, as shown by a patient who had a prolonged progression-free survival interval after receiving anlotinib treatment.
Background: Fibroblast growth factor receptor (FGFR) fusions in non-small cell lung cancer (NSCLC) are small genomic events. At present, there is no standard treatment strategy for patients with NSCLC carrying an FGFR fusion. Case Presentation: We report the case of a 45-year-old female patient who was diagnosed with lung adenocarcinoma and underwent right upper lobectomy and postoperative adjuvant chemotherapy. After 13 months, the patient???s lung lesions progressed. Next generation sequencing of venous blood and lung tissues confirmed an FGFR2-ERC1 fusion, and she received chemotherapy and immunotherapy. Two months later, the patient???s lung lesions progressed again. Based on the target effect of anlotinib on FGFR, the patient was subsequently treated with anlotinib, and the progression-free survival interval exceeded 8.0 months. Conclusion: These findings showed that patients with lung adenocarcinoma carrying an FGFR2-ERC1 fusion gene may benefit from anlotinib. This case provided evidence to support the use of anlotinib in the treatment of NSCLC patients with FGFR fusion gene subtypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据